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Saudi Journal of Ophthalmology (2013) 27, 129–132EditorialOcular tumors: Triumphs, challenges and controversiesThe pediatric malignancy retinoblastoma is the most com-
mon intraocular tumor in the world, reflecting the rarity of
uveal melanoma in populous nations like China and India.1,2
Kivelä has estimated that there are approximately 8000 retin-
oblastomas yearly in the world and about 1000 fewer uveal
melanomas, which typically occur in older adults.2
Retinoblastoma is one of the great therapeutic success
stories of pediatric oncology. Untreated retinoblastoma is al-
most invariably fatal. Early in the twentieth century survival in
children with retinoblastoma was only 5%. This improved to
30% in 1930 as a result of more accurate diagnosis and newer
therapies such as radiation. Today, survival in developed
countries is 95% and approaches 100% at some centers,
where the major cause of death is now due to secondary can-
cers that develop in patients with germline mutations. Che-
motherapy, one of the factors responsible for the marked
improvement in survival, has revolutionized the treatment
of retinoblastoma during the last several decades. Treatment
regimens include the intravenous administration of chemo-
therapeutic agents, direct targeting of the tumor by adminis-
tration via the ophthalmic artery, and most recently,
intravitreal injection of melphalan to target vitreous seeds.
Chemoreduction is a potentially eye-sparing procedure
that employs intravenous systemic chemotherapy, typically
comprising multiples cycles of vincristine, etoposide and car-
boplatin, to shrink tumors so they become amenable to local
therapies like cryotherapy or thermotherapy. This combined
therapy can eradicate tumors and save eyes that once re-
quired enucleation.3,4
Eyes with advanced retinoblastoma still require enucle-
ation, particularly if there is concern for optic nerve or choroi-
dal invasion. The addition of adjuvant chemotherapy to these
‘‘high-risk’’ eyes has markedly improved survival.5 Adjuvant
chemotherapy is administered if histopathologic examination
of enucleated eyes discloses certain high-risk features includ-
ing massive choroidal invasion, invasion of the optic nerve
posterior to the lamina cribrosa or to the surgical margin,
or the combination of lesser degrees of uveal and optic nerve
invasion.6 These features are believed to place a patient at
high-risk for metastasis. Anterior chamber involvement is also
considered to be a high-risk feature, but its significance is less
certain. Intravenous chemotherapy kills retinoblastoma cells
that have metastasized from the primary intraocular tumor.
In addition, it is thought to decrease the frequency of pineo-
blastoma, a potentially fatal retinoblastoma-like tumor of the
pineal gland that can develop in patients with germline
retinoblastoma.7,8Peer review under responsibility
of Saudi Ophthalmological Society,
King Saud UniversityIntra-arterial chemotherapy (IAC) of retinoblastoma was
initially developed by Kaneko and colleagues as an eye-pre-
serving therapy in Japan where enucleation is abhorrent for
cultural reasons.9,10 In recent years, the technique was ex-
plored by Gobin and Abramson in New York and Jabbour
and Shields in Philadelphia and has been adopted elsewhere
for selected cases.11–20 In this procedure, chemotherapeutic
drugs are directly administered to the tumor-containing eye
via a catheter inserted within or in close proximity to the oph-
thalmic artery. The catheter is introduced into the femoral ar-
tery and advanced under fluoroscopic guidance.
The topic of intra-arterial chemotherapy is somewhat con-
troversial. Theoretically, the technique should decrease po-
tential complications of systemic chemotherapy since the
drugs are only administered to the eye. The latter is not en-
tirely true, however, since the development of neutropenia
in some cases indicates that the drugs do have some systemic
effect. Intra-arterial chemotherapy can totally eradicate retin-
oblastomas in many instances, and spectacular treatment re-
sults have been reported. However, the technique has its
limitations and does not work in all cases. The fact that IAC
treats just the eye can be a major advantage and disadvan-
tage at the same time. The advantage stems from its tar-
geted delivery to the single organ, but the disadvantage
results from its presumed inability to control systemic metas-
tasis. Compared to systemic chemotherapy administered
intravenously, IAC theoretically carries a higher risk for meta-
static disease. At least one in five eyes enucleated for retino-
blastoma harbor high-risk features that serve as an indication
for adjuvant systemic intravenous chemotherapy.21 These
high-risk features will not be detected if IAC is performed,
and extraocular tumor cells at remote sites might not be con-
trolled because the chemotherapy is delivered solely to the
eye. Similarly, the treatment might not effectively control
pineoblastomas. High-risk features such as optic nerve and
uveal invasion have been found histopathologically in eyes
enucleated after IAC.21,22
Other complications of IAC such as ischemic chorioretinal
atrophy have been observed clinically and confirmed histop-
athologically.21,23 A retrospective study of eyes enucleated
after IAC disclosed thrombosed vessels containing particu-
lates of foreign material or chemotherapy precipitates intro-
duced during therapy.21 Experimental studies in nonhuman
primates and clinical observations during infusion in infants
have shown pulsatile optic nerve and choroidal blanching,
retinal artery narrowing, and retinal artery precipitates, rais-
ing additional concerns about IAC and the vascular toxicity
of melphalan.24–27Production and hosting by Elsevier
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130 EditorialSeeds of tumor in the vitreous are an important cause of
treatment failure after a variety of conservative treatments
including IAC. In the past several years, intravitreal injection
of the alkylating agent melphalan has shown promise in treat-
ing this complication, which typically necessitates enucle-
ation.28,29 A proper dose of melphalan, currently stated to
be 20–30 lg is necessary. Lower doses fail to control the tu-
mor seeds, while higher doses (50 lg) are toxic and cause
phthisis bulbi. Prevailing opinions about the safety of intraoc-
ular injections or the use of fine needle biopsy in eyes with
retinoblastoma are evolving. Retinoblastoma has a soft fria-
ble consistency and a propensity to contaminate needle
tracts. In the past, clinicians were cautioned to avoid needle
biopsy because the risk of extraocular tumor extension and
orbital dissemination was considered high. However, such
complications have not been encountered because the new
intravitreal injection technique incorporates safeguards
including post-injection cryotherapy to the injection site.28
Uveal melanoma is the most common intraocular tumor in
Europe and the United States. This malignancy has a definite
predilection for fair-skinned patients of European ancestry.
Uveal melanoma affects both sexes equally and typically
arises during the sixth decade. Although there have been ma-
jor advances in the diagnosis, treatment and prognostic
assessment of uveal melanoma in recent years, survival has
remained essentially unchanged from 1973 to 2008.30 About
one half of patients with melanoma of the posterior uvea de-
velop metastatic disease and succumb to their tumor.31 The
tumor metastasizes hematogenously and the liver is typically
involved. Because certain prognostic factors, which will be
discussed below, are less common in smaller tumors, it is
hoped that the early treatment of smaller lesions might im-
prove survival.
One of the major clinical challenges faced by ophthalmol-
ogists is determining whether a small pigmented lesion is a
benign nevus or a melanoma that should be treated expedi-
tiously while it has a better prognosis. Based on a review of
1329 cases on a file on the Oncology Service at the Wills
Eye Hospital, Dr. Carol Shields and her team identified cer-
tain clinical tumor parameters that suggest that a pigmented
lesion will grow and probably is a melanoma that warrants
treatment.32,33 These parameters are included in the mne-
monic ‘‘To Find Small Ocular Melanoma Using Helpful Hints
Daily’’.33 The initial ‘‘T’’ denotes thickness greater than
2 mm, ‘‘F’’ stands for subretinal fluid, ‘‘S’’ for symptoms,
‘‘O’’ for the presence of an orange pigment on the surface
of the tumor, and ‘‘M’’ the location of the posterior margin
of the tumor less than 3 mm from the optic disc. The ‘‘UH’’
refers to ultransonic hollowness on B scan ultrasonography,
the absence of ‘‘H’’ halo and ‘‘D’’ drusen. New diagnostic
techniques that facilitate these assessments are now avail-
able. Spectral domain optical coherence tomography (OCT)
aids the detection of subretinal fluid, while fundus autofluo-
rescence (FAF) imaging helps to disclose and confirm the
presence of the orange pigment. The latter comprises a fluo-
rescent lipofuscin pigment within macrophages released
from disrupted RPE cells on the surface of an actively grow-
ing tumor.34 More recently, enhanced depth imaging OCT
has shown promise in the differential diagnosis of choroidal
lesions.35
There are a number of prognostic factors that suggest
whether a patient with uveal melanoma is at risk to developmetastatic disease and die. The most important factors that
can be assessed on routine clinical examination include the
size of the tumor, and the presence of ciliary body involve-
ment and extraocular extension.1,36 Additional factors dis-
closed during routine histopathologic examination of
enucleated eyes include cellular characteristics of the tumor
called cell type, mitotic activity as the number of mitotic fig-
ures counted in 40 high power fields, lymphocytic and mela-
nophagic infiltration, and microvascular networks called
vascular mimicry patterns.
Tumors that contain epithelioid cells have a poorer prog-
nosis compared to spindle cell melanomas. Epithelioid mela-
noma cells have sharply demarcated cytoplasmic margins
and large round or oval nuclei with prominent nucleoli. Pure
epithelioid cell tumors are rare, but nearly 90% of the mela-
nomas enucleated in the Collaborative Ocular Melanoma
Study were mixed cell tumors that contained epithelioid cells
as well as spindle cells.37 Tumors composed entirely of spin-
dle cells have a better prognosis. The presence of many infil-
trating lymphocytes within a tumor also indicates a poorer
prognosis.38,39 The basis for this somewhat counterintuitive
observation rests in the unique immune privileged status of
the eye; it is thought that tumor cells must exit the globe
to elicit an immune response.
The most powerful prognostic indicators of uveal mela-
noma require special testing. These tests include assessment
of the tumor cells for certain nonrandom chromosomal
abnormalities, most notably monosomy of chromosome 3,
and the expression (up or down regulation) of certain genes
by the tumors cells. The latter is called gene expression pro-
filing. 50% of patients whose tumors have monosomy 3 die
within 3 years of enucleation. The prognosis of patients with
disomy 3 is poorer if chromosome 8 is amplified.40–42
Both DNA evaluation with chromosomal study and RNA
evaluation with gene expression profiling (GEP) are useful
for prognostication. Gene expression profiling using micro-
array analysis stratifies uveal melanoma patients into two
classes that differ markedly in prognosis.42–45 Class I tumors,
whose GEP resembles melanocytes, rarely metastasize. In
contrast, patients with class 2 tumors have more than a
90% risk of developing metastatic disease. The GEP of class
2 tumors resembles primitive neuronal or ectodermal stem
cells, and class 2 tumors typically have monosomy 3 as well
as typical high risk histopathologic features including epithe-
lioid cells and vascular mimicry patterns.46,47 The test is able
to determine tumor class by examining only 15 genes and is
remarkably accurate, but this remains controversial.48,49
It has been found that 84% of class 2 melanomas have
mutations in the BAP1 gene (breast cancer 1, early onset
(BRCA1)-associated protein-1 gene), which is located on
chromosome 3.50 Monosomy of chromosome 3 is thought
to disclose inactivating mutations in this gene. Mutations in
the in the GNAQ or GNA11 genes are found in 50% of uveal
melanomas.51,52 The latter are thought to be an early or initi-
ating event because they are also found in benign precursor
lesions like congenital ocular melanocytosis.
Many centers are now submitting specimens for DNA
(chromosomal) or RNA (GEP) testing. Our center performs
both testing methods in collaboration with the genetics team
at the University of Pennsylvania. Others still rely on mono-
somy 3, which can be assessed using several methods.53,54
One of the controversies surrounding the use of these
Editorial 131powerful ancillary tests is based on the current lack of a ther-
apy that can successfully treat metastatic uveal melanoma.55
The tests identify patients at risk, but clinicians currently have
no treatment available that can effectively treat micrometa-
static disease, which is believed to be present before patients
become symptomatic and are seen by the ophthalmologist.56
Of course, determining that a patient is in a low risk category
does psychologically provide patient relief and could de-
crease the need for surveillance. In addition, both DNA and
RNA sampling are helpful in selecting ‘‘at-risk’’ patients for
enrollment in clinical trials investigating new chemotherapeu-
tic agents.
Tumors of the orbit and ocular adnexa also present addi-
tional challenges and some aspects of therapy are controver-
sial as well. Adenoid cystic carcinoma, the most common
malignancy of the lacrimal gland continues to have a dismal
prognosis. Sentinel node biopsy for conjunctival melanoma
and sebaceous carcinoma has its advocates, but its effect
on outcome remains controversial.57,58 New targeted medi-
cal therapies based on molecular biology are now available.
Interferon alpha-2b is used to treat ocular surface squamous
neoplasms59, the oral agent vismodegib can control ad-
vanced basal cell carcinoma by inhibiting the cellular hedge-
hog pathway,60 and the monoclonal antibody rituximab,
which targets the protein CD20 on the surface of B cells, is
a treatment option for many B cell lymphomas.61 These excit-
ing new additions to our therapeutic armamentarium appear
to be effective, but several are quite expensive.
In summary, ocular oncology has witnessed a tremendous
evolution in diagnostic and therapeutic strategies. In devel-
oped countries, we have triumphed over retinoblastoma
and the prevention of metastatic disease, thanks to new che-
motherapeutic regimens and delivery methods. With mela-
noma, we have better ways to detect small tumors and
hopefully improve survival. Additionally we can powerfully
predict prognosis with DNA or RNA testing, but the chal-
lenge and controversy remain in improving systemic thera-
pies for those with poor prognostic findings.References
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